Targeted tumor tissue enhanced sorafenib ferroptosis liposome and preparation method and application thereof
By using liposomes targeting tumor tissue to encapsulate sorafenib and sodium butyrate in tumor tissue, the problem of insufficient sensitivity to ferrodysfunction inducers is solved, and targeted delivery and sustained release of drugs are achieved. It significantly improves the sensitivity and immune response of tumor cells, effectively inhibiting the growth of tumors such as colorectal cancer.
Patent Information
- Application Number
- CN202411149432.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-15
AI Technical Summary
Some tumors are not sensitive to ferrodysfunction inducers. How to improve the sensitivity of tumor cells to ferrodysfunction inducers remains a huge challenge, especially in tumor treatment.
Using liposomes targeting tumor tissues, sorafenib and sodium butyrate are encapsulated into liposomes in a specific proportion to form a bilayer or concentric multilayer enclosed structure. Sorafenib is a fat-soluble structure. Sodium acid is a water-soluble structure that is modified on the surface of the sphere to achieve targeted delivery and sustained release of drugs, and improve the concentration and utilization of drugs in tumor tissues.
Effectively improve the sensitivity of tumor cells to ferrous death, promote immunogenic death and anti-tumor immune response, overcome the problems of low effective concentration and drug resistance in tumor treatment, and significantly enhance the colorectal cancer and other Tumor inhibitory effect.
Smart Images

Figure CN118948770A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a liposome, in particular to a liposome targeting tumor tissue and enhancing sorafenib ferroptosis, and also to a preparation method and application of the liposome. Background Art
[0002] Ferroptosis is a type of programmed cell death characterized by iron-dependent lipid peroxidation and decreased glutathione peroxidase activity. It is also an immunogenic death. Early ferroptosis can release damage-related molecular patterns, promote dendritic cell maturation, and trigger T cell-mediated adaptive immunity.
[0003] At present, many small molecule compounds such as sorafenib, Erastin, RSL3, iFSP1, sulfasalazine, etc. have been confirmed to promote ferroptosis in animal tumor models of colorectal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, and breast cancer. Sorafenib is a multi-target kinase inhibitor that inhibits CRAF, BRAF, V600EBRAF, c-Kit, FLT-3 in tumor cell targets and CRAF, VEGFR-2, VEGFR-3, and PDGFR-β in tumor vascular targets, inducing cell apoptosis. At the same time, sorafenib is also a ferroptosis inducer, which has been shown to promote ferroptosis mainly by inhibiting system Xc- and increasing intracellular iron levels. Ferroptosis has attracted much attention in tumor treatment, but some tumors are not sensitive enough to ferroptosis inducers. How to improve the sensitivity of tumor cells to ferroptosis inducers remains a huge challenge. Summary of the invention
[0004] Purpose of the invention: The purpose of the present invention is to provide a liposome that targets tumor tissue and enhances sorafenib ferroptosis, and also provides a method for preparing the above-mentioned liposome, and its application in enhancing tumor ferroptosis and inducing immunogenic death to promote the maturation and antigen presentation of dendritic cells, and promote the anti-tumor immune response of CD8+T cells.
[0005] Technical solution: The liposomes of the present invention that target tumor tissues and enhance sorafenib ferroptosis are ferroptosis-inducing drug delivery systems that encapsulate sorafenib and sodium butyrate, wherein the mass ratio of sorafenib to sodium butyrate is 1:200-250.
[0006] The liposome includes lecithin, and the mass ratio of sorafenib to lecithin is 1:15-25. The particle size of the liposome is 60-150 nm; the liposome is a closed spherical structure with a double layer (single layer) and / or concentric multiple double layers (multilayers) enclosing a central water cavity, sorafenib is a fat-soluble structure doped in the lipid bilayer, sodium butyrate is a water-soluble structure included in the lipid bilayer, and the surface of the sphere is modified with butyric acid.
[0007] The method for preparing the above-mentioned liposomes that target tumor tissue and enhance sorafenib ferroptosis comprises the following steps:
[0008] (1) dissolving lecithin and sorafenib in ethanol to obtain an ethanol mixture;
[0009] (2) injecting the ethanol mixture into the sodium butyrate aqueous solution to obtain an ethanol liposome dispersion;
[0010] (3) removing ethanol from the ethanol liposome dispersion by evaporation and centrifuging to obtain liposomes that target tumor tissue and enhance sorafenib ferroptosis.
[0011] Wherein, in step (1), the concentration of ethanol in the ethanol mixture is 95% to 100%.
[0012] Specifically, step (2) comprises injecting the ethanol mixture into the rapidly stirred sodium butyrate aqueous solution at a constant rate, wherein the constant rate is 0.5 to 1 ml / min; and the rapid stirring speed is 400 to 500 r / min.
[0013] Wherein, in step (2), the concentration of ethanol in the ethanol liposome dispersion is 5 to 30 v / v%.
[0014] Wherein, in step (3), the evaporation is rotary evaporation, 45°C, 1000 rpm, and the evaporation time is 10 to 20 min.
[0015] The invention also discloses the use of the liposomes targeting tumor tissues and enhancing sorafenib ferroptosis in the preparation of targeted anti-tumor drugs.
[0016] Wherein, the tumor is colorectal cancer, subcutaneous tumor or carcinoma in situ.
[0017] Specifically, the application is that sorafenib and sodium butyrate in liposomes enhance ferroptosis of tumor tissues, induce immunogenic death, promote maturation and antigen presentation of dendritic cells, and promote anti-tumor immune response of CD8+T cells.
[0018] Principle of the invention: The present invention prepares sodium butyrate at a synergistic dose with the ferroptosis inducer sorafenib into liposomes and delivers them to tumor tissues; it solves the problem of poor sensitivity of drug-induced ferroptosis in colorectal cancer (CRC) and provides a potential effective target for the treatment of CRC.
[0019] Specifically, the liposome of the present invention is a closed spherical structure with a double layer (single layer) and / or concentric multiple double layers (multilayers) enclosing the central water cavity, sorafenib is a fat-soluble structure, doped in the lipid bilayer, sodium butyrate is a water-soluble structure, included in the lipid bilayer, and the surface of the sphere is modified with butyric acid, which is very similar to the cell membrane, has good biocompatibility, and is degradable in vivo. Advantages, therefore, can achieve targeted sustained release of drugs in diseased tissues, effectively improve drug utilization, and reduce toxic side effects. The ferroptosis inducer drug delivery system is a liposome (Lipso@NaB) encapsulated with sorafenib and sodium butyrate, and the surface is simultaneously modified with butyric acid, which can effectively target tumor tissues, solve the problem of low effective concentration of traditional drugs, and play a good anti-tumor effect.
[0020] Furthermore, sorafenib and sodium butyrate were loaded into liposomes at a mass ratio of 1:200-250. Regarding the synergistic ferroptosis-promoting effects of sorafenib and sodium butyrate at concentration ratios of 1:50, 1:100, 1:200, and 1:400, the study found that the synergistic effect of sodium butyrate and sorafenib was best at a concentration of 1:200-1:250. Below this concentration ratio, the synergistic ferroptosis-promoting effect of sodium butyrate and sorafenib was not ideal, and above this concentration, the encapsulation rate and drug loading rate of the sorafenib drug would decrease.
[0021] In terms of in vitro efficacy, Lipso@NaB liposomes can effectively enhance and sensitize the ferroptosis of colorectal cancer, while promoting immunogenic death and enhancing the anti-tumor immune response of Lipso@NaB liposomes. Compared with traditional drugs that easily make colorectal cancer resistant to ferroptosis, Lipso@NaB liposomes combine sorafenib and sodium butyrate at a synergistic dose to effectively overcome the ferroptosis resistance of cancer. At the same time, Lipso@NaB liposomes will generate new pathway mechanisms to achieve the anti-tumor effect of drugs.
[0022] In terms of in vivo efficacy, the Lipso@NaB liposomes prepared by the present invention can achieve effective anti-tumor effects by enhancing the ferroptosis effect of sorafenib in principle. At the same time, it can further effectively induce immune responses in mice through the ferroptosis effect of tumors, and can effectively promote the maturation and antigen presentation of dendritic cells through tumor immunogenic death, and promote CD8 + T cell anti-tumor immune response, effectively promoting CD8+T cells (IFN-γ + CD8 + T and GZMB + CD8 +The invention can inhibit the infiltration and activation of T cells, inhibit the infiltration of Treg cells and M-MDSC, and promote the increase of type I interferon (IFN-I) level in the tumor microenvironment. The effective immune response can overcome the defects of the existing technology and achieve the inhibition of subcutaneous tumors and carcinoma in situ in animals.
[0023] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The liposomes of the present invention have good biocompatibility and are degradable in vivo, and can be targeted and sustained-released in diseased tissues, effectively improving drug utilization and reducing toxic side effects; (2) When used in anti-tumor treatment, they can effectively overcome the ferroptosis resistance of cancer, induce immunogenic death, promote the maturation and antigen presentation of dendritic cells, and promote the anti-tumor immune response of CD8+T cells; (3) The preparation method is simple, the conditions are mild, and it is suitable for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 It is a particle size test for the preparation method of liposomes that targets tumor tissues to enhance sorafenib ferroptosis and promote anti-tumor immunity;
[0025] Figure 2 is the synergistic effect of cck8 detection under different ratios of lipso@NaB liposomes, where A and B are the synergistic ferroptosis-promoting effects of free drugs at different molar mass concentration ratios and the corresponding synergistic coefficients, C and D are the synergistic ferroptosis-promoting effects of liposome drugs at different molar mass concentration ratios and the corresponding synergistic coefficients, and E is the cell apoptosis at the best synergistic concentration ratio of 1:1000;
[0026] Figure 3 This is a graph showing the uptake of lipso@NaB liposomes by tumor cells in vitro;
[0027] Figure 4 The distribution of lipso@NaB liposomes in the tumor at different times. A, B, and C are the changes of liposomes in the tumor at 4h, 8h, and 24h in different treatment groups, respectively.
[0028] Figure 5 This is the result of lipso@NaB liposomes enhancing ferroptosis; A, B, and C are the changes in MDA, Fe2+, and GSH in CT26 cells treated with different liposomes, respectively;
[0029] Figure 6 This is the result of lipso@NaB liposomes enhancing immunogenic death. A, B, and C are the changes of HMGB1, ATP, and Calreticulin in CT26 cells treated with different liposomes, respectively. DETAILED DESCRIPTION
[0030] The technical scheme of the present invention is further described below in conjunction with the examples. The test materials used in the examples can all be purchased through conventional channels.
[0031] Example 1
[0032] The preparation method of the liposomes targeting tumor tissue and enhancing sorafenib ferroptosis of the present invention comprises the following steps:
[0033] (1) dissolving 10 mg of lecithin and 0.5 mg of sorafenib in 500 μl of anhydrous ethanol to obtain an ethanol mixture;
[0034] (2) injecting the ethanol mixture at a constant rate into 4.5 ml of a rapidly stirred sodium butyrate aqueous solution at a stirring speed of 500 r / min to produce an ethanol liposome dispersion with an ethanol concentration of 10% (vol / vol);
[0035] (3) The obtained ethanol liposome dispersion was transferred to a rotary evaporator to remove ethanol. Subsequently, the solution was centrifuged (3000 g, 20 minutes) to precipitate unencapsulated drugs or large particles to obtain liposomes lipso@NaB that target tumor tissues and enhance sorafenib ferroptosis.
[0036] The prepared liposomes targeting tumor tissue to enhance sorafenib ferroptosis were diluted 1:5, and their particle sizes were measured using Zetasizer Nano by dynamic light scattering (DLS) and electrophoretic light scattering (ELS) methods, respectively. The morphological characteristics of Lipso@NaB can be visualized by transmission electron microscopy. Figure 1 As shown in the figure, the particle size detected by particle size analysis is between 60 and 150 nm.
[0037] For cell and animal experiments, liposomes were suspended in ultrapure water, sterilized by filtration through a 0.2 μm filter, and stored at 4 °C.
[0038] Example 2
[0039] Experimental study on the efficacy of the liposomes of the present invention in treating colorectal cancer:
[0040] Lipso@NaB liposomes were prepared by using different molar mass concentration ratios (sorafenib: sodium butyrate = 1:250, 1:500, 1:1000, 1:2000, 1:4000). After being sterilized by filtration through a 0.2 μm filter, the concentration of sorafenib was determined and used as the concentration standard. The cells were added to CT26 cells in a 96-well plate, and the half inhibitory concentration (IC50) of Lipso@NaB liposomes with different molar mass concentration ratios was detected by cck8 experiment. The optimal synergistic dose was explored by calculation. The results are as follows: Figure 2As shown, it can be seen that there is a drug synergistic effect between sorafenib and sodium butyrate in the Lipso@NaB liposomes prepared with different molar mass concentration ratios, and the optimal synergistic concentration ratio is 1:1000. Subsequent experiments were carried out using Lipso@NaB liposomes prepared with (sorafenib: sodium butyrate = 1:200-250).
[0041] Example 3
[0042] In vitro targeting of the liposomes of the present invention was investigated:
[0043] Coumarin 6 (C6) was used as a fluorescent probe to replace sorafenib in the ferroptosis inducer drug delivery system. Considering that sodium butyrate also has a cell-killing effect, liposomes with different molar mass concentration ratios were prepared by reducing the concentration. Free C6, LipC6, and LipC6@NaB (the molar concentration ratios of lecithin and sodium butyrate were 10:0, 10:1, and 1:1, respectively, and the final concentration of C6 was 0.5ug / ml) were added to the colorectal cancer cell line CT26 for treatment. The uptake of the drug delivery system (green) by the colorectal cancer cell line CT26 was observed under a laser confocal microscope at 3h and 6h, respectively. The results are shown in Figure 3 The experimental results show that, in the same period of time, compared with free C6 and pure liposome C6, liposomes encapsulated with different concentrations of sodium butyrate can increase the uptake of CT26 in a dose-dependent manner, indicating that the ferroptosis inducer drug delivery system has stronger targeting to tumor cells.
[0044] Example 4
[0045] In vivo targeting of the liposomes of the present invention was investigated:
[0046] A Balb / c mouse inguinal subcutaneous tumor-bearing model (murine colon cancer CT26) was established. The drug was administered intravenously after the tumor grew to about 5-10 mm in diameter. In vivo imaging of the mice was performed 4, 8, and 24 hours later. The near-infrared dye DiR was used as a fluorescent probe to replace sorafenib in the ferroptosis inducer drug delivery system, and liposomes with corresponding concentrations of butyric acid were added to study the in vivo targeting distribution characteristics of liposomes under the synergy of butyric acid. The results are shown in the figure. Figure 4 As shown by Figure 4 It can be seen that in the in vivo imaging at 4h, 8h, and 24h after administration, the liposomes with butyrate added (LipDiR@NaB) have higher enrichment concentration and longer residence time than the liposomes without butyrate (LipDiR) and the free DiR group. This indicates that the liposomes with butyrate added (LipDiR@NaB) injected through the tail vein have good targeting and longer metabolic time in tumor tissues.
[0047] Example 5
[0048] To explore the sensitization effect of liposomes synergized with butyrate (Lipso@NaB) on sorafenib ferroptosis:
[0049] By testing the common indicators of ferroptosis, MDA, Fe2+, and GSH, the results are as follows Figure 5 As shown in the figure, it was found that Lipso@NaB can significantly enhance the ferroptosis effect of sorafenib compared with Lip@Sora and Lip@NaB groups. At the same time, Lipso@NaB liposomes can significantly promote the generation of reactive oxygen species and lipid peroxides in tumor cells CT26. By detecting the immunogenic death indicators induced by Lipso@NaB liposomes, the results are shown in Figure 6 As shown, Lipso@NaB liposomes promoted the release of damage-associated molecular patterns (DAMPs), mainly including calreticulin, high mobility group protein 1 (HMGB1) and adenosine triphosphate (ATP) on the surface of tumor cells, indicating that the liposomes of the present invention can enhance immunogenic death by synergistically promoting ferroptosis.
Claims
1. A liposome targeting tumor tissue to enhance sorafenib ferroptosis, characterized in that: The liposome is a ferroptosis inducing drug delivery system encapsulating sorafenib and sodium butyrate, wherein the mass ratio of sorafenib to sodium butyrate is 1:200-250.
2. The liposome according to claim 1, characterized in that The liposome comprises lecithin, and the mass ratio of sorafenib to lecithin is 1:15-25.
3. The liposome according to claim 1, characterized in that The particle size of the liposome is 60 to 150 nm.
4. A method for preparing the liposome targeting tumor tissue and enhancing sorafenib ferroptosis according to claim 1, characterized in that: The following steps are involved: (1) dissolving lecithin and sorafenib in ethanol to obtain an ethanol mixture; (2) injecting the ethanol mixture into the sodium butyrate aqueous solution to obtain an ethanol liposome dispersion; (3) removing ethanol from the ethanol liposome dispersion by evaporation and centrifuging to obtain liposomes that target tumor tissue and enhance sorafenib ferroptosis.
5. The method according to claim 4, characterized in that: In step (1), the concentration of ethanol in the ethanol mixture is 95% to 100%.
6. The method according to claim 4, characterized in that: Step (2) specifically comprises injecting the ethanol mixture into the rapidly stirred sodium butyrate aqueous solution at a constant rate, wherein the constant rate is 0.5-1 ml / min; and the speed of the rapid stirring is 400-500 r / min.
7. The method according to claim 4, characterized in that: In step (2), the concentration of ethanol in the ethanol liposome dispersion is 5 to 30 v / v%.
8. The method according to claim 4, characterized in that: In step (3), the evaporation is rotary evaporation, and the evaporation time is 10 to 20 minutes.
9. Use of the liposome targeting tumor tissue and enhancing sorafenib ferroptosis according to claim 1 in the preparation of targeted anti-tumor drugs.
10. The use according to claim 9, characterized in that: The application is specifically that sorafenib and sodium butyrate in liposomes enhance ferroptosis of tumor tissues, induce immunogenic death, promote maturation and antigen presentation of dendritic cells, and promote anti-tumor immune response of CD8+T cells.
